Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients. A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. The purpose of this study is to

Trial Details

NCT ID
NCT03895359
Phase
PHASE3
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Stereotactic Body Radiation
  • Transarterial Chemoembolization
Locations (sample)
  • London, Ontario, Canada|42.98339,-81.23304

Key Eligibility Criteria

  • Primary hepatobiliary cancer confirmed pathologically
  • Non - lymphoma liver metastases confirmed pathologically
  • Radiographic liver lesions most consistent with metastases, in a patient with known pathologically proven non - lymphoma cancer and a previously ne…
  • Hepatocellular carcinoma diagnosed with vascular enhancement of the lesion consistent with hepatocellular carcinoma, and with an elevated AFP, in t…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →